Description: Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada.
Home Page: www.neoleukin.com
NLTX Technical Analysis
188 East Blaine Street
Seattle,
WA
98102
United States
Phone:
855 226 6447
Officers
| Name | Title |
|---|---|
| Dr. Jonathan G. Drachman M.D. | CEO, Pres, Principal Financial Officer & Director |
| Dr. Priti Patel M.D., M.S. | Chief Medical Officer |
| Dr. David Baker | Co-founder & Member of Scientific Advisory Board |
| Mr. Sean Michael Smith | Principal Accounting Officer, VP of Fin. & Controller |
| Ms. Donna M. Cochener-Metcalfe J.D. | Gen. Counsel & Sr. VP of Legal |
| Dr. Carl Walkey Ph.D. | Sr. VP of Corp. Devel. |
| Mr. Kamran Alam | Sr. Strategic Advisor |
| Dr. Bill Arthur | VP & Head of Research |
| Mr. Umut Ulge | VP of Clinical Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1855 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-03-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 77 |